Linperlisib combined with VRD for newly diagnosed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of drugs—linperlisib plus the standard VRD regimen (bortezomib, lenalidomide, and dexamethasone)—for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding linperlisib can improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with active multiple myeloma and have not had prior treatment, except for a short course of steroids or radiation.
- You are between 18 and 65 years old and considered eligible for a stem cell transplant using your own cells.
- You have a measurable sign of myeloma, such as a high level of M-protein in your blood or urine, or a tumor that can be seen on a scan.
- Your blood counts (neutrophils and platelets) and liver and kidney function are within a certain range to safely handle the treatment.
- Your heart function is stable (ejection fraction at least 40%) and you do not have severe heart disease or nerve damage.
- You are willing to use effective contraception during the study if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests the best combination of medicines for newly diagnosed multiple myeloma patients who are headed to an autologous stem cell transplant (ASCT). It compares extended VRD plus versus Isa-VRD versus Isa-V-Iberdomide to see which approach works best and is tolerable.
This early-phase study tests whether selinexor combined with VRd (bortezomib, lenalidomide, and dexamethasone) can improve outcomes for people with high-risk, newly diagnosed multiple myeloma. You may be a candidate if you have certain lab/genetic signs of “high-risk” disease and haven’t had prior myeloma treatment.
This trial tests whether REGN17372 plus linvoseltamab is safe for people with multiple myeloma that has come back or not responded to prior treatments. You may join if you have tried at least 3 other therapies.
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.